Increased immunity to FRα has been reported in patients with FRα-expressing ovarian cancer in comparison to healthy controls, suggesting that this may be a target for cell-based and peptide immunotherapies [23]. This evidence concerns the gene FOLR1 and ovarian carcinoma.